205 related articles for article (PubMed ID: 34029766)
1. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.
Rodriguez N; Lee J; Flynn L; Murray F; Devlin SM; Soto C; Cho C; Dahi P; Giralt S; Perales MA; Sauter C; Ponce DM
Transplant Cell Ther; 2021 Nov; 27(11):920.e1-920.e9. PubMed ID: 34029766
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance.
Puckrin R; Kwan ACF; Blosser N; Leyshon C; Duggan P; Daly A; Zepeda V; Stewart D; Chaudhry A; Storek J; Jamani K
Cytotherapy; 2023 Oct; 25(10):1101-1106. PubMed ID: 37306643
[TBL] [Abstract][Full Text] [Related]
4. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.
Chhabra S; Visotcky A; Pasquini MC; Zhu F; Tang X; Zhang MJ; Thompson R; Abedin S; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Douglas Rizzo J; Runaas L; Saber W; Shah NN; Shaw BE; Horowitz MM; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1876-1885. PubMed ID: 32653622
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
7. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
8. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
9. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.
Bashir Q; Nishihori T; Pasquini MC; Martens MJ; Wu J; Alsina M; Anasetti C; Brunstein C; Dawson P; Efebera Y; Gasparetto C; Geller N; Giralt S; Hall AC; Koreth J; McCarthy P; Scott E; Stadtmauer EA; Vesole DH; Hari P
Transplant Cell Ther; 2023 Jun; 29(6):358.e1-358.e7. PubMed ID: 35840087
[TBL] [Abstract][Full Text] [Related]
10. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
11. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
12. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT.
Schäfer H; Blümel-Lehmann J; Ihorst G; Bertz H; Wäsch R; Zeiser R; Finke J; Marks R
Ann Hematol; 2021 Aug; 100(8):2095-2103. PubMed ID: 33755792
[TBL] [Abstract][Full Text] [Related]
13. Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.
Reshef R; Ganetsky A; Acosta EP; Blauser R; Crisalli L; McGraw J; Frey NV; Hexner EO; Hoxie JA; Loren AW; Luger SM; Mangan J; Stadtmauer EA; Mick R; Vonderheide RH; Porter DL
Biol Blood Marrow Transplant; 2019 Mar; 25(3):515-521. PubMed ID: 30315941
[TBL] [Abstract][Full Text] [Related]
14. Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.
Ueda Oshima M; Storer BE; Qiu H; Chauncey T; Asch J; Boyer MW; Giaccone L; Flowers M; Mielcarek M; Storb R; Maloney DG; Sandmaier BM
Transplant Cell Ther; 2021 Feb; 27(2):163.e1-163.e7. PubMed ID: 33830025
[TBL] [Abstract][Full Text] [Related]
15. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
Kanate AS; Hari PN; Pasquini MC; Visotcky A; Ahn KW; Boyd J; Guru Murthy GS; Rizzo JD; Saber W; Drobyski W; Michaelis L; Atallah E; Carlson KS; D'Souza A; Fenske TS; Cumpston A; Bunner P; Craig M; Horowitz MM; Hamadani M
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1295-1302. PubMed ID: 28412518
[TBL] [Abstract][Full Text] [Related]
16. Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.
Al-Homsi AS; Goodyke A; McLane M; Abdel-Mageed S; Cole K; Muilenburg M; Feng Y
Biol Blood Marrow Transplant; 2017 Feb; 23(2):255-261. PubMed ID: 27888016
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
18. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
Hamadani M; Gibson LF; Remick SC; Wen S; Petros W; Tse W; Brundage KM; Vos JA; Cumpston A; Bunner P; Craig MD
J Clin Oncol; 2013 Dec; 31(35):4416-23. PubMed ID: 24166529
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
[TBL] [Abstract][Full Text] [Related]
20. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant.
Solomon SR; Solh M; Zhang X; Brown S; Jackson KC; Holland HK; Morris LE; Bashey A
Blood Adv; 2020 Aug; 4(15):3669-3676. PubMed ID: 32777064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]